Analysts forecast that Kamada Ltd. (NASDAQ:KMDA) will report earnings per share of $0.15 for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Kamada’s earnings, with the lowest EPS estimate coming in at $0.11 and the highest estimate coming in at $0.19. Kamada posted earnings of $0.16 per share in the same quarter last year, which suggests a negative year-over-year growth rate of 6.3%. The firm is scheduled to report its next earnings report on Wednesday, February 6th.
According to Zacks, analysts expect that Kamada will report full year earnings of $0.27 per share for the current fiscal year, with EPS estimates ranging from $0.23 to $0.30. For the next financial year, analysts expect that the business will report earnings of $0.35 per share, with EPS estimates ranging from $0.31 to $0.38. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Kamada.
Kamada (NASDAQ:KMDA) last issued its earnings results on Monday, November 12th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.05). Kamada had a return on equity of 11.70% and a net margin of 10.60%. The firm had revenue of $14.98 million during the quarter, compared to the consensus estimate of $25.99 million.
A number of analysts have commented on KMDA shares. BidaskClub raised shares of Kamada from a “hold” rating to a “buy” rating in a report on Thursday, September 27th. Zacks Investment Research lowered shares of Kamada from a “hold” rating to a “sell” rating in a research report on Thursday, November 15th. Finally, HC Wainwright set a $11.00 price objective on shares of Kamada and gave the company a “buy” rating in a research report on Wednesday, August 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $8.08.
Shares of KMDA traded down $0.19 during mid-day trading on Wednesday, hitting $5.20. 9,861 shares of the company traded hands, compared to its average volume of 7,067. Kamada has a 1 year low of $4.26 and a 1 year high of $6.45. The stock has a market capitalization of $210.18 million, a price-to-earnings ratio of 28.89 and a beta of 1.32. The company has a quick ratio of 3.31, a current ratio of 4.86 and a debt-to-equity ratio of 0.01.
Several large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in Kamada in the 2nd quarter worth approximately $146,000. Macquarie Group Ltd. raised its position in Kamada by 71.7% during the 2nd quarter. Macquarie Group Ltd. now owns 47,547 shares of the biotechnology company’s stock worth $247,000 after buying an additional 19,851 shares during the last quarter. ARK Investment Management LLC increased its holdings in shares of Kamada by 14.8% during the 2nd quarter. ARK Investment Management LLC now owns 119,537 shares of the biotechnology company’s stock valued at $616,000 after purchasing an additional 15,440 shares in the last quarter. Worth Venture Partners LLC increased its holdings in shares of Kamada by 203.4% during the 3rd quarter. Worth Venture Partners LLC now owns 155,719 shares of the biotechnology company’s stock valued at $963,000 after purchasing an additional 104,397 shares in the last quarter. Finally, Acadian Asset Management LLC increased its holdings in shares of Kamada by 157.8% during the 2nd quarter. Acadian Asset Management LLC now owns 292,795 shares of the biotechnology company’s stock valued at $1,507,000 after purchasing an additional 179,237 shares in the last quarter. Institutional investors and hedge funds own 12.51% of the company’s stock.
Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin deficiency (AATD).
See Also: Stock Symbols and CUSIP Explained
Get a free copy of the Zacks research report on Kamada (KMDA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.